Stealth BioTherapeutics Corp (MITO) is a leading biotechnology business based in the US. In the week up to 6 June Stealth BioTherapeutics shares surged 26.28% to a closing position of $1.73. However, over the last 12 months, Stealth BioTherapeutics's share price has fallen by 22.34% from $1.97. Stealth BioTherapeutics is listed on the NASDAQ and employs 29 staff. All prices are listed in US Dollars.
Since the stock market crash that started in February 2020, Stealth BioTherapeutics's share price has had significant negative movement.
Its last market close was $1.37, which is 35.98% down on its pre-crash value of $2.14 and 52.19% up on the lowest point reached during the March 2020 crash when the shares fell as low as $0.9002.
If you had bought $1,000 worth of Stealth BioTherapeutics shares at the start of February 2020, those shares would have been worth $440.04 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $548.00.
|52-week range||$1.06 - $2.5|
|50-day moving average||$1.4117|
|200-day moving average||$1.5379|
|Wall St. target price||$3.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.674|
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-06-11)||-4.38%|
|1 month (2021-05-19)||15.04%|
|3 months (2021-03-19)||-22.73%|
|6 months (2020-12-18)||4.08%|
|1 year (2020-06-19)||-22.34%|
|2 years (2019-06-19)||-88.00%|
|Revenue TTM||$21.1 million|
|Gross profit TTM||$21.1 million|
|Return on assets TTM||-83.53%|
|Return on equity TTM||-1666.63%|
|Market capitalisation||$84.5 million|
TTM: trailing 12 months
There are currently 789,092 Stealth BioTherapeutics shares held short by investors – that's known as the "short interest". This figure is 49.5% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting Stealth BioTherapeutics shares can be evaluated.
Stealth BioTherapeutics's "short interest ratio" (SIR) is the quantity of Stealth BioTherapeutics shares currently shorted divided by the average quantity of Stealth BioTherapeutics shares traded daily (recently around 11.3 million). Stealth BioTherapeutics's SIR currently stands at 0.07. In other words for every 100,000 Stealth BioTherapeutics shares traded daily on the market, roughly 70 shares are currently held short.
However Stealth BioTherapeutics's short interest can also be evaluated against the total number of Stealth BioTherapeutics shares, or, against the total number of tradable Stealth BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stealth BioTherapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Stealth BioTherapeutics shares in existence, roughly 10 shares are currently held short) or 0.0428% of the tradable shares (for every 100,000 tradable Stealth BioTherapeutics shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Stealth BioTherapeutics.
Find out more about how you can short Stealth BioTherapeutics stock.
We're not expecting Stealth BioTherapeutics to pay a dividend over the next 12 months. Typically it's companies that have been around for longer that pay dividends (Stealth BioTherapeutics had its IPO on 15 February 2019). However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Stealth BioTherapeutics's shares have ranged in value from as little as $1.06 up to $2.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Stealth BioTherapeutics's is 2.0205. This would suggest that Stealth BioTherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Ever wondered how to buy shares in Gaucho Group? We explain how and compare a range of providers that can give you access to many brands, including Gaucho Group.
Ever wondered how to buy shares in AST SpaceMobile? We explain how and compare a range of providers that can give you access to many brands, including AST SpaceMobile.
Learn more about Orphazyme’s recent performance and where you can invest in Orphazyme shares. We also run through some helpful rules of thumb for any investor.
Upgrade your summer lovin’ style with the most recent release from fashion staples I Saw It First and Olivia. Shop the new collab now!
This guide will show you step-by-step instructions on how to buy the Adamant (ADDY) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Polycat Finance (FISH) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Eleven Finance (ELE) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the WaultSwap Polygon (WEXPOLY) token as well as a list of exchanges you can trade it on.
Bring the full gym experience into your home with NordicTrack’s Commercial 2950, a treadmill packed with interactive features.
Find out what we thought of NAGA, a trading platform that lets you t trade more than 500 financial instruments and copy other people’s trades.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.